Close menu




August 17th, 2023 | 07:10 CEST

Cantourage, Amazon, Bayer: Young entrants soaring, old players in reorientation

  • Cannabis
  • ecommerce
  • chemicals
Photo credits: pixabay.com

The time has finally come in Germany: the federal government has given the green light for the private use of cannabis. Since 2017, doctors in Germany have been allowed to prescribe cannabis as a therapeutic agent. The growing market in this segment has been recognized by the team at Cantourage, which focuses on the medical production of active ingredients from the hemp plant. The leadership of Bayer could use some relief. Analysts at Berenberg Bank have put the Leverkusen-based company's balance sheet through its paces and discovered a few things that have now downgraded Bayer's stock from Buy to Hold. Amazon's Cloud Business takes another step forward. The Company's in-house AI is moving into the documentation of medical health reports. Find out what it is all about here.

time to read: 5 minutes | Author: Juliane Zielonka
ISIN: CANTOURAGE GROUP SE | DE000A3DSV01 , AMAZON.COM INC. DL-_01 | US0231351067 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    German hemp startup Cantourage: Traffic light government votes for cannabis legalization

    Finally, in Germany as well: the legalization of cannabis has been approved by the federal cabinet. In the future, it will be permitted for adult German citizens to purchase up to 25 g of cannabis and to possess up to 3 plants for self-cultivation. The fact that the active ingredients of the hemp plant are also used medicinally is something that some investors are not even aware of yet. Since 2017, doctors in Germany have been allowed to prescribe cannabidiol, especially to patients suffering from acute and chronic pain. This is the case for rheumatism and also multiple sclerosis (MS).

    Some investors may still have painful memories of Juicy Fields. The dubious platform was exposed on a large-scale investment fraud.

    But it is a completely different story with the German-founded company Cantourage. The Berlin-based company is dedicated to making cannabis available for the medical market. The team continuously works to reduce therapy costs, develop innovative medicines, and import high-quality cannabis flowers from global sources. Their global collaboration network currently extends to 40 companies in the cultivation and manufacturing sectors. Cantourage's products are sold in German and European pharmacies.

    A solid business from the ground up in a growth market, whose team preferred to go public on the Frankfurt Stock Exchange rather than let venture capital investors talk them into their strategy. And success proves them right: In the first half of 2023, the Company recorded revenues of over EUR 11 million from the production and sale of medical cannabis, an increase of about 90% compared to last year. CEO Philip Schetter expects revenue growth in 2023 to be in the higher double-digit percentage range. The goal is for the Company to continue to expand profitably. Currently, Cantourage's share price is EUR 11.34 on the stock exchange.

    The Cantourage founding team, Norman Ruchholtz, Florian Holzapfel and Patrick Hoffman, are experienced players in the cannabis industry. Back in 2015, they founded Pedanios, one of the first major cannabis wholesalers in Europe, which they sold two years later to Canadian market leader Aurora. They continued their business under the name Aurora Deutschland GmbH and then in 2019, they founded Cantourage. Since the cannabis market is often volatile, the team decided to go public to raise cash. Thanks to its strong retailer network and in-house brand strategy of offering cannabis in a wide variety of price segments, the Company can look forward to continued growth. And so can investors. Here is the latest covering.

    Amazon ventures into the healthcare market again - This time, with generative AI

    Retail giant, Amazon has tried its hand at the healthcare market before. Be it with the idea of sending medicines by drone, its own pharmacy division or a call-a-doctor service. But the pioneers were unsuccessful because the healthcare market regulations are particularly tightly knit.

    Now there is a silver lining in the cloud segment of the Seattle-based group. AWS announced AWS HealthScribe, a new generative AI-driven service that automatically creates clinical documentation. Specialists such as interventional radiologists need to document their cases. Previously done via dictaphone to be typed up by the assistant, now an AWS AI can do it.

    At the AWS Summit in New York, AWS HealthScribe was unveiled, a new HIPAA-approved service that allows healthcare software providers to develop clinical applications with speech recognition and generative AI. This saves physicians time by automatically generating clinical documentation.

    Using AWS HealthScribe, healthcare software providers can create comprehensive transcripts, extract key details, and generate summaries of physician-patient conversations through a single API. These can then be entered into an electronic health record (EHR) system. By citing the source of each line of generated text from the original conversation transcript, AWS HealthScribe enables responsible AI system deployment, making it easier for physicians to review clinical notes before entering them into the EHR.

    So the group is sneaking into healthcare once again through a small backdoor with big potential. The healthcare AI market size was EUR 5.9 billion in 2021 and is expected to grow to EUR 184 billion by 2030. That represents a compound annual growth rate (CAGR) of 45.5% from 2023 to 2030.

    Berenberg Bank upgrades Bayer to "hold"

    Berenberg Bank lowered its rating on Bayer AG to "hold" from "buy," citing issues such as legal disputes, corporate bureaucracy and debt levels, according to Reuters. It appears that the new Bayer CEO will first have to do a major housecleaning until the tradition-rich Leverkusen-based company gets back on track.

    According to Berenberg, estimated legal liabilities of EUR 9 billion, downgrades caused by agriculture-related earnings declines, and a more than 9-fold 2023 EV/EBITDA (Enterprise Value to EBITDA ratio) have led to the shares being "not cheap." Downgrades in accounting refer to the group's dwindling ability to settle its liabilities with excess cash from revenues after deducting expenses.

    Berenberg Bank adds that Bayer is expected to struggle to grow profits over the next two years due to loss of exclusivity and lower commodity prices.

    The rationale for the purchase has increasingly become a bet on whether Bayer will be able to successfully settle or defend against the polychlorinated biphenyls (PCB) cases. In this regard, Bayer's track record to date is not inspiring, Berenberg said.

    In addition, Berenberg analysts note that the dividend is not expected to be covered in 2023. Prioritizing dividends over net debt reduction would worry the broker given legal risks.

    Bayer shares were down 2% to EUR 50.85. The average price target for the next 12 months is EUR 66, based on reports from analyst firms over the past year.


    The medical cannabis market is currently being conquered by Berlin-based Cantourage. In H1 2023, the Company generated revenues of over EUR 11 million from the production and sale of medical cannabis - an increase of about 90% YOY. CEO Philip Schetter expects revenue growth in the higher double-digit percentage range for 2023. Cantourage's share price currently stands at EUR 11.34. Berenberg Bank lowered its rating on Bayer AG from "buy" to "hold," citing issues such as legal disputes, corporate bureaucracy and debt levels. The challenges for Bayer's new CEO are apparent. Amazon announces AWS HealthScribe, a new service that automatically creates clinical documentation. This HIPAA-approved service allows healthcare software providers to develop clinical applications with speech recognition and generative AI. It saves physicians time by automatically creating clinical documentation.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST

    70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!

    • Mining
    • Tungsten
    • hightech
    • chemicals
    • Biotechnology

    Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?

    Read

    Commented by Juliane Zielonka on June 13th, 2024 | 06:45 CEST

    Carbon Done Right, Amazon, BASF after the EU elections - Which Green Economy Deals are really worthwhile?

    • Sustainability
    • CarbonCredits
    • chemicals
    • Retail

    The European Green Deal is a comprehensive initiative of the European Union to tackle the challenges of climate change and promote a sustainable economy. The key elements include reducing greenhouse gas emissions by at least 55% by 2030, promoting clean mobility and the circular economy, and preserving biodiversity. The green parties have lost around 20 seats in the European Parliament. What is the general situation regarding sustainability efforts to reduce CO₂ emissions? Carbon Done Right is a Canadian company that trades its own CO₂ emission certificates through reforestation and afforestation to facilitate barter deals with major players like Microsoft and Tesla. They offer satellite monitoring of tradeable areas via a dashboard for all participants. Amazon is also entering the agricultural market. In Southeast Asia, the IT company Axons uses AWS technology to improve local food cultivation. BASF, a well-known conglomerate and chemical giant, is now researching an active ingredient obtained from natural mammalian bacteria capable of producing low-CO₂ substances for the chemical industry. Where is an investment worthwhile?

    Read

    Commented by Stefan Feulner on May 27th, 2024 | 07:30 CEST

    Rheinmetall, Saturn Oil + Gas, Canopy Growth - Financial sustainability as a return booster

    • Mining
    • Oil
    • Defense
    • Cannabis

    Sustainability is one of the most significant issues of our time, including on the stock market. In the past, ESG-labeled investments have sprung up like mushrooms. In contrast, investments in socially and ecologically harmful sectors were avoided at the expense of returns. When looking at performance, a striking number of top performers come from sectors such as armaments, oil and gas or cannabis. Listed companies from these sectors are likely to continue their upward trend in the future.

    Read